赛默飞世尔科技 2024年度报告

Our Mission is to enable our customers to make the worldHealthier, CleanerandSafer Our Mission is our purpose:To enable our customers to make the worldhealthier, cleanerandsafer. To ourshareholders,customersandcolleagues $4.6 billion returned to our shareholders throughshare repurchases and dividends. Throughout the years, we have remained true to aproven growth strategy that continues to propel oursuccess. Our strategy consists of three pillars: •Delivering high-impact innovation •Deepening our trusted partner status withour customers Thank you for your ongoing support ofThermo Fisher Scientific. Together, we are buildinga brighter future for our company, and I’m excitedabout the opportunities ahead of us as wecontinue to deliver for all of our stakeholders. •Building on our unparalleled commercial engine We made great progress in executing this strategyin 2024, and our investments are driving growth andfurther enhancing our industry leadership. I’ll sharesome highlights of our progress during the yearacross these pillars. Thermo Fisher’s Mission is to enable our customersto make the world healthier, cleaner and safer, andour customers rely on us as their trusted partner tohelp them advance discoveries that are improvinglives around the world. Thank you to our 125,000colleagues whose passion for our Mission makesour success possible. High-impact innovation Beginning with the first pillar, our focus on innovationenables our customers to address some of theworld’s greatest challenges. In 2024, we invested$1.4 billion in R&D to deliver exciting new technologiesacross our businesses that are helping our customersbreak new ground in their important work. There aremany great examples across our company, and I’llhighlight just a few. Reflecting on 2024, I’m very proud of what weachieved as we continued to enable the success ofour customers, created value for our shareholdersand made a positive impact on society. Differentiated financial performance In terms of our financial results, we delivereddifferentiated performance in 2024. This includedrevenue of $42.88 billion, GAAP diluted earnings pershare (EPS) of $16.53 and adjusted EPS* of $21.86,along with free cash flow* of $7.3 billion. In addition,we deployed $7.7 billion of capital – $3.1 billionthrough M&A with the acquisition of Olink and Marc N. Casper Chairman, President and CEO Strong trackrecord ofperformance In chromatography and mass spectrometry,the year was highlighted by the launch of ourThermo Scientific™Stellar™mass spectrometer, whichcomplements our award-winning Thermo Scientific™Orbitrap™Astral™mass spectrometer launched in2023 by validating biomarker candidates of interestto advance clinical research. It’s been great to seethe significant impact these two instruments arehaving on advancing science and transforming fieldslike proteomics. Both received industry recognitionin 2024. In the R&D 100 Awards, the Astral massspectrometer won gold in the Market Disruptor specialrecognition category as one of the most significantadvancements in mass spectrometry in 15 years.And, in Lab Innovations’ Lab Awards, the Stellar massspectrometer was recognized in the categoryof Best Technology Innovation. Also in chromatography and mass spectrometry, welaunched the Thermo Scientific™Dionex™Inuvion™ion chromatography system, which streamlinesenvironmental testing in industrial and appliedsettings, and the Thermo Scientific™iCAP™MXSeries ICP-MS, an inductively coupled plasma massspectrometry platform designed to streamline traceelemental analysis for environmental, food, industrialand research laboratories. In electron microscopy, we launched theThermo Scientific™Iliad™scanning transmissionelectron microscope, which integrates a number ofour advanced analytical technologies into a seamlessand user-friendly workflow to enable the developmentof advanced materials. In life sciences solutions, we launched the AppliedBiosystems™MagMAX™Sequential DNA/RNA Kit,which maximizes the isolation of DNA and RNAfrom blood cancer samples, helping researchersidentify unique insights into cancer-causing geneticalterations. We also introduced new additions to theGibco™CTS™Detachable Dynabeads™platform tofurther enhance development and manufacturing oflife-changing cell therapies. Revenue ProfileRevenueProfile As you can see, it was another spectacular yearof innovation, and we have an exciting pipeline forthe future. Our trusted partner statusand unparalleled commercial engine During the year, we continued to strengthen ourindustry-leading commercial engine and deepen ourtrusted partner status with customers to acceleratetheir innovation and enhance their productivity. To meet our customers’ current and future needs, weexpanded our pharma services and clinical researchcapabilities in the U.S. and Europe. In addition, weintroduced our Accelerator™Drug Developmentsolution. This truly unique offering leverages ourcombined contract development and manufacturinga